ALNY - Alnylam Pharmaceuticals Inc Stock Price, Fair Value and News

143.80USD-2.27 (-1.55%)Market Closed

Market Summary

USD143.80-2.27

Market Closed

-1.55%

ALNY Stock Price

View Fullscreen

ALNY RSI Chart

ALNY Valuation

Market Cap

18.4B

Price/Earnings (Trailing)

-41.79

Price/Sales (Trailing)

10.06

EV/EBITDA

-72.04

Price/Free Cashflow

438.6

ALNY Price/Sales (Trailing)

ALNY Profitability

EBT Margin

-23.71%

Return on Equity

199.53%

Return on Assets

-11.49%

Free Cashflow Yield

0.23%

ALNY Fundamentals

ALNY Revenue

Revenue (TTM)

1.8B

Rev. Growth (Yr)

31.25%

Rev. Growth (Qtr)

-41.41%

ALNY Earnings

Earnings (TTM)

-440.2M

Earnings Growth (Yr)

33.55%

Earnings Growth (Qtr)

-193.31%

Breaking Down ALNY Revenue

Last 7 days

-0.4%

Last 30 days

-0.3%

Last 90 days

-21.1%

Trailing 12 Months

-28.7%

How does ALNY drawdown profile look like?

ALNY Financial Health

Current Ratio

3.08

Debt/Equity

-4.63

Debt/Cashflow

0.1

ALNY Investor Care

Shares Dilution (1Y)

1.63%

Diluted EPS (TTM)

-3.54

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.1B	1.2B	1.7B	1.8B
2022	880.0M	884.2M	960.9M	1.0B
2021	570.9M	687.5M	749.3M	844.3M
2020	285.9M	345.2M	401.0M	492.9M
2019	86.3M	101.1M	169.1M	219.8M
2018	92.9M	106.8M	91.8M	74.9M
2017	58.8M	66.0M	69.4M	89.9M
2016	29.9M	29.9M	37.3M	47.2M
2015	60.8M	62.2M	57.6M	41.1M
2014	36.8M	35.4M	37.4M	50.6M
2013	64.8M	52.6M	44.8M	47.2M
2012	82.4M	82.7M	78.7M	66.7M
2011	96.4M	90.4M	83.5M	82.8M
2010	100.0M	102.1M	105.5M	100.0M
2009	0	97.6M	99.1M	100.5M
2008	0	0	0	96.2M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Alnylam Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 01, 2024	tanguler tolga	acquired	-	-	4,751	evp, chief commercial officer
Mar 01, 2024	greenstreet yvonne	acquired	-	-	23,754	chief executive officer
Mar 01, 2024	garg pushkal	acquired	-	-	4,751	cmo & evp dev & med affairs
Mar 01, 2024	poulton jeffrey v.	acquired	-	-	7,741	evp, chief financial officer
Feb 29, 2024	sharp phillip a	sold	-4,540,070	151	-30,000	-
Feb 29, 2024	sharp phillip a	acquired	1,777,500	59.25	30,000	-
Feb 28, 2024	greenstreet yvonne	sold	-455,357	155	-2,932	chief executive officer
Feb 28, 2024	tanguler tolga	sold	-77,805	155	-501	evp, chief commercial officer
Feb 28, 2024	garg pushkal	sold	-89,144	155	-574	cmo & evp dev & med affairs
Feb 28, 2024	franchini indrani lall	sold	-51,094	155	-329	evp, clo & secretary

Which funds bought or sold ALNY recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	added	35.26	24,672	464,341	-%
Apr 22, 2024	IFM Investors Pty Ltd	added	3.14	-927,458	3,833,540	0.04%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	added	6.17	-467,626	2,266,860	-%
Apr 22, 2024	EFG Asset Management (Americas) Corp.	reduced	-33.01	-1,483,690	1,626,910	0.50%
Apr 22, 2024	MetLife Investment Management, LLC	reduced	-1.39	76,779	1,244,930	0.01%
Apr 22, 2024	CKW FINANCIAL GROUP	unchanged	-	-7,000	31,000	-%
Apr 22, 2024	GraniteShares Advisors LLC	added	13.87	-59,231	474,803	0.25%
Apr 22, 2024	ALTFEST L J & CO INC	added	1.3	-83,000	314,000	0.04%
Apr 19, 2024	Wealthfront Advisers LLC	reduced	-30.17	-1,008,440	1,209,050	-%
Apr 19, 2024	VALLEY NATIONAL ADVISERS INC	reduced	-82.56	-14,000	2,000	-%

Are Funds Buying or Selling ALNY?

Are funds buying ALNY calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ALNY

No. of Funds

Unveiling Alnylam Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.52%	11,943,895	SC 13G/A
Feb 09, 2024	capital world investors	13.1%	16,398,889	SC 13G/A
Feb 09, 2024	wellington management group llp	5.78%	7,252,907	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 29, 2024	baillie gifford & co	5.55%	6,967,097	SC 13G/A
Jan 26, 2024	blackrock inc.	6.8%	8,546,557	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	3.3%	4,074,144	SC 13G/A
Feb 13, 2023	capital world investors	13.5%	16,593,958	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	9.35%	11,507,116	SC 13G/A

Recent SEC filings of Alnylam Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 01, 2024	ARS	ARS
Apr 01, 2024	DEF 14A	DEF 14A
Apr 01, 2024	DEFA14A	DEFA14A
Mar 28, 2024	3	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 04, 2024	8-K	Current Report
Mar 01, 2024	4	Insider Trading

Peers (Alternatives to Alnylam Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	2.33%	-21.90%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.36%	-10.84%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-10.64%	-48.02%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	8.01%	271.09%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-10.76%	0.48%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	76.15%	62.71%	-0.25	2.14	-13.45%	66.37%

Alnylam Pharmaceuticals Inc News

Latest updates

Alnylam Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-41.4%	439,718,000	750,530,000	318,754,000	319,290,000	335,035,000	264,306,000	224,818,000	213,259,000	258,535,000	187,633,000	220,553,000	177,566,000	163,562,000	125,853,000	103,962,000	99,476,000	71,681,000	70,061,000	44,714,000	33,294,000	21,033,000
Costs and Expenses	3.6%	556,122,000	536,663,000	548,585,000	469,097,000	523,649,000	522,346,000	416,504,000	359,991,000	453,096,000	369,310,000	366,713,000	363,820,000	357,784,000	351,052,000	302,821,000	309,634,000	369,754,000	286,360,000	280,985,000	222,082,000	241,389,000
S&GA Expenses	-0.5%	198,123,000	199,175,000	214,689,000	183,659,000	210,344,000	235,859,000	169,984,000	154,471,000	186,382,000	142,075,000	145,323,000	146,859,000	166,291,000	167,472,000	127,896,000	126,761,000	156,277,000	120,351,000	112,769,000	89,608,000	108,688,000
R&D Expenses	7.5%	272,141,000	253,179,000	248,526,000	230,569,000	262,039,000	245,371,000	205,712,000	169,893,000	229,050,000	194,572,000	182,635,000	185,899,000	168,469,000	161,783,000	154,996,000	169,571,000	201,301,000	160,796,000	163,890,000	129,127,000	131,036,000
EBITDA Margin	25.8%	-0.14	-0.19	-0.71	-0.76	-0.89	-1.02	-0.88	-0.79	-0.78	-0.87	-1.04	-1.25	-	-	-	-	-	-	-	-	-
Interest Expenses	1.4%	31,338,000	30,893,000	30,035,000	28,955,000	29,913,000	41,084,000	42,609,000	42,362,000	36,816,000	40,274,000	33,416,000	32,515,000	28,517,000	28,731,000	27,248,000	-	-	-	-	-	-
Income Taxes	-93.9%	183,000	2,988,000	1,815,000	1,739,000	472,000	-23,000	2,729,000	985,000	-1,842,000	278,000	1,228,000	1,016,000	-59,000	839,000	1,326,000	575,000	-398,000	-394,000	960,000	695,000	361,000
Earnings Before Taxes	-191.3%	-137,687,000	150,741,000	-274,209,000	-172,362,000	-207,021,000	-405,943,000	-274,673,000	-239,356,000	-260,302,000	-204,236,000	-188,331,000	-199,275,000	-243,599,000	-252,452,000	-177,903,000	-181,646,000	-276,583,000	-208,929,000	-218,521,000	-181,220,000	-211,080,000
EBT Margin	18.7%	-0.24	-0.29	-0.86	-0.93	-1.09	-1.23	-1.11	-1.01	-1.01	-1.11	-1.29	-1.53	-	-	-	-	-	-	-	-	-
Net Income	-193.3%	-137,870,000	147,753,000	-276,024,000	-174,101,000	-207,493,000	-405,920,000	-277,402,000	-240,341,000	-258,460,000	-204,514,000	-189,559,000	-200,291,000	-243,540,000	-253,291,000	-179,229,000	-182,221,000	-276,185,000	-208,535,000	-219,481,000	-181,915,000	-211,441,000
Net Income Margin	18.6%	-0.24	-0.30	-0.86	-0.93	-1.09	-1.23	-1.11	-1.01	-1.01	-1.12	-1.29	-1.53	-	-	-	-	-	-	-	-	-
Free Cashflow	-113.2%	-45,104,000	342,320,000	-74,905,000	-180,366,000	-153,613,000	-131,794,000	-138,874,000	-189,052,000	-172,027,000	-160,098,000	-133,102,000	-252,838,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-0.2%	3,830	3,839	3,402	3,392	3,546	3,535	3,330	3,434	3,643	3,472	3,509	3,255	3,407	3,307	3,374	2,280	2,395	2,542	2,716	2,014	1,575
Current Assets	-0.1%	2,983	2,985	2,524	2,541	2,692	2,691	2,472	2,590	2,809	2,675	2,725	2,470	2,615	2,555	2,160	1,585	1,716	1,897	2,064	1,392	1,201
Cash Equivalents	-21.3%	813	1,033	658	672	866	1,073	576	534	820	1,094	746	380	499	497	581	468	547	923	1,136	725	420
Inventory	-6.9%	89.00	96.00	100	132	129	115	89.00	79.00	86.00	98.00	84.00	74.00	75.00	67.00	77.00	68.00	56.00	55.00	41.00	32.00	24.00
Net PPE	0.1%	526	526	527	523	523	515	508	504	502	485	471	465	465	445	439	430	425	396	372	342	321
Liabilities	1.1%	4,051	4,005	3,811	3,651	3,705	3,603	3,154	3,032	3,055	2,716	2,656	2,329	2,391	2,092	1,975	930	956	935	959	467	273
Current Liabilities	1.9%	968	950	789	673	768	773	658	606	696	611	555	495	585	480	384	339	353	353	329	149	179
Long Term Debt	0.1%	1,021	1,020	1,019	1,018	1,017	1,016	678	677	-	434	433	192	191	-	-	-	-	-	-	-	-
LT Debt, Non Current	0.1%	1,021	1,020	1,019	1,018	1,017	1,016	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-Infinity%	-220	-	-	-	-158	-	176	401	588	756	853	926	1,016	1,215	1,400	1,350	1,439	1,607	1,757	1,547	1,302
Retained Earnings	-2.0%	-7,009	-6,871	-7,019	-6,743	-6,569	-6,361	-5,955	-5,678	-5,438	-5,179	-4,975	-4,785	-4,585	-4,341	-4,088	-3,909	-3,727	-3,450	-3,242	-3,022	-2,840
Additional Paid-In Capital	1.1%	6,811	6,737	6,647	6,522	6,455	6,337	6,173	6,117	6,058	5,969	5,863	5,747	5,644	5,593	5,520	5,290	5,201	5,091	5,034	4,602	4,175
Shares Outstanding	0.3%	126	125	125	124	124	122	121	120	118	119	117	117	-	-	-	-	-	-	-	-	-
Float	-	-	-	23,650	-	-	-	17,596	-	-	-	19,997	-	-	-	16,993	-	-	-	7,997	-	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-108.3%	-29.79	359	-58.99	-166	-131	-115	-122	-171	-150	-134	-121	-235	-123	-110	-135	-246	-195	-182	289	-188	-150
Share Based Compensation	-34.3%	42.00	64.00	76.00	40.00	43.00	128	30.00	29.00	45.00	33.00	32.00	56.00	34.00	37.00	34.00	35.00	66.00	46.00	31.00	32.00	28.00
Cashflow From Investing	-2135.7%	-240	-10.76	-8.71	-76.22	-139	314	143	-147	-413	-88.27	157	71.00	-97.89	-10.09	-441	114	-220	-10.08	-289	103	249
Cashflow From Financing	18.4%	39.00	33.00	53.00	46.00	63.00	297	30.00	35.00	292	574	330	51.00	218	34.00	689	54.00	40.00	-20.70	413	391	5.00

ALNY Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenues	$ 1,828,292	$ 1,037,418	$ 844,287
Operating costs and expenses:
Cost of goods sold	268,216	140,174	115,005
Cost of collaborations and royalties	42,190	28,643	25,139
Research and development	1,004,415	883,015	792,156
Selling, general and administrative	795,646	770,658	620,639
Total operating costs and expenses	2,110,467	1,822,490	1,552,939
Loss from operations	(282,175)	(785,072)	(708,652)
Other (expense) income:
Interest expense	(121,221)	(155,968)	(143,021)
Interest income	95,561	24,808	1,579
Other expense, net	(125,682)	(134,175)	(2,050)
Loss on the extinguishment of debt	0	(76,586)	0
Total other expense, net	(151,342)	(341,921)	(143,492)
Loss before income taxes	(433,517)	(1,126,993)	(852,144)
Provision for income taxes	(6,725)	(4,163)	(680)
Net loss	$ (440,242)	$ (1,131,156)	$ (852,824)
Net loss per common share, basic (in dollars per share)	$ (3.52)	$ (9.30)	$ (7.20)
Net loss per common share, diluted (in dollars per share)	$ (3.52)	$ (9.30)	$ (7.20)
Weighted average common shares, basic (in shares)	124,906,000	121,689,000	118,451,000
Weighted average common shares, diluted (in shares)	124,906,000	121,689,000	118,451,000
Statements of Comprehensive Loss
Net income (loss)	$ (440,242)	$ (1,131,156)	$ (852,824)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	11,018	(7,840)	(1,978)
Foreign currency translation gain (loss)	11,922	(5,274)	11,398
Defined benefit pension plans, net of tax	(1,661)	1,719	943
Total other comprehensive income (loss)	21,279	(11,395)	10,363
Comprehensive loss	(418,963)	(1,142,551)	(842,461)
Net product revenues
Revenues:
Total revenues	1,241,474	894,329	662,138
Net revenues from collaborations
Revenues:
Total revenues	546,185	134,912	180,953
Royalty revenue
Revenues:
Total revenues	$ 40,633	$ 8,177	$ 1,196

ALNY Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 812,688	$ 866,394
Marketable debt securities	1,615,516	1,297,890
Marketable equity securities	11,178	28,122
Accounts receivable, net	327,787	237,963
Inventory	89,146	128,962
Prepaid expenses and other current assets	126,382	132,916
Total current assets	2,982,697	2,692,247
Property, plant and equipment, net	526,057	523,494
Operating lease right-of-use assets	199,732	215,136
Restricted investments	49,391	49,390
Other assets	72,003	66,092
Total assets	3,829,880	3,546,359
Current liabilities:
Accounts payable	55,519	98,094
Accrued expenses	713,013	545,460
Operating lease liability	41,510	41,967
Deferred revenue	102,753	42,105
Liability related to the sale of future royalties	54,991	40,289
Total current liabilities	967,786	767,915
Operating lease liability, net of current portion	243,101	261,339
Deferred revenue, net of current portion	188,175	193,791
Convertible debt	1,020,776	1,016,942
Liability related to the sale of future royalties, net of current portion	1,322,248	1,252,015
Other liabilities	308,438	212,580
Total liabilities	4,050,524	3,704,582
Commitments and contingencies (Note 13)
Stockholders’ deficit:
Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of December 31, 2023 and December 31, 2022	0	0
Common stock, $0.01 par value per share, 250,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; 125,794 shares issued and outstanding as of December 31, 2023; 123,925 shares issued and outstanding as of December 31, 2022	1,259	1,240
Additional paid-in capital	6,811,063	6,454,540
Accumulated other comprehensive loss	(23,375)	(44,654)
Accumulated deficit	(7,009,591)	(6,569,349)
Total stockholders’ deficit	(220,644)	(158,223)
Total liabilities and stockholders’ deficit	$ 3,829,880	$ 3,546,359

About Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB
WEBSITE	alnylam.com
INDUSTRY	Biotechnology
EMPLOYEES	2002

Alnylam Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Alnylam Pharmaceuticals Inc? What does ALNY stand for in stocks?

ALNY is the stock ticker symbol of Alnylam Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alnylam Pharmaceuticals Inc (ALNY)?

As of Tue Apr 23 2024, market cap of Alnylam Pharmaceuticals Inc is 18.4 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALNY stock?

You can check ALNY's fair value in chart for subscribers.

What is the fair value of ALNY stock?

You can check ALNY's fair value in chart for subscribers. The fair value of Alnylam Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Alnylam Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALNY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Alnylam Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ALNY is over valued or under valued. Whether Alnylam Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Alnylam Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALNY.

What is Alnylam Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, ALNY's PE ratio (Price to Earnings) is -41.79 and Price to Sales (PS) ratio is 10.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALNY PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Alnylam Pharmaceuticals Inc's stock?

In the past 10 years, Alnylam Pharmaceuticals Inc has provided 0.115 (multiply by 100 for percentage) rate of return.